Milbar Laboratories Warned for Contaminated Product

Drug Industry Daily
A A
The FDA sent a warning letter to Connecticut-based drugmaker Milbar Laboratories for quality deficiencies and failure to investigate out-of-specification batches.

To View This Article:

Login

Subscribe To Drug Industry Daily